PURPOSE: We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease. DESIGN: We performed a comprehensive review of the English-language literature on IBC through computerized literature searches. RESULTS: Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (∼30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC. CONCLUSION: Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.
PURPOSE: We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease. DESIGN: We performed a comprehensive review of the English-language literature on IBC through computerized literature searches. RESULTS: Significant advances in imaging, including digital mammography, high-resolution ultrasonography with Doppler capabilities, magnetic resonance imaging, and positron emission tomography-computed tomography, have improved the diagnosis and staging of IBC. There are currently no established molecular criteria for distinguishing IBC from noninflammatory breast cancer. Such criteria would be helpful for the diagnosis and development of novel targeted therapies. Combinations of neoadjuvant systemic chemotherapy, surgery, and radiation therapy have led to an improved prognosis; however, the overall 5-year survival rate for patients with IBC remains very low (∼30%). Sentinel lymph node biopsy and skin-sparing mastectomy are not recommended for patients with IBC. CONCLUSION: Optimal management of IBC requires close coordination among medical, surgical, and radiation oncologists, as well as radiologists and pathologists. There is a need to identify molecular changes that define the pathogenesis of IBC to enable eradication of IBC with the use of IBC-specific targeted therapies.
Authors: Suparna Bonthala Wedam; Jennifer A Low; Sherry X Yang; Catherine K Chow; Peter Choyke; David Danforth; Stephen M Hewitt; Arlene Berman; Seth M Steinberg; David J Liewehr; Jonathan Plehn; Arpi Doshi; Dave Thomasson; Nicole McCarthy; Hartmut Koeppen; Mark Sherman; JoAnne Zujewski; Kevin Camphausen; Helen Chen; Sandra M Swain Journal: J Clin Oncol Date: 2006-01-03 Impact factor: 44.544
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron Journal: N Engl J Med Date: 2006-12-28 Impact factor: 91.245
Authors: Steven Van Laere; Ilse Van der Auwera; Gert G Van den Eynden; Stephen B Fox; Fabrizio Bianchi; Adrian L Harris; Peter van Dam; Eric A Van Marck; Peter B Vermeulen; Luc Y Dirix Journal: Breast Cancer Res Treat Date: 2005-10 Impact factor: 4.872
Authors: Dang M Nguyen; Kathy Sam; Anna Tsimelzon; Xiaoxian Li; Helen Wong; Syed Mohsin; Gary M Clark; Susan G Hilsenbeck; Richard M Elledge; D Craig Allred; Peter O'Connell; Jenny C Chang Journal: Clin Cancer Res Date: 2006-09-01 Impact factor: 12.531
Authors: Ana M Gonzalez-Angulo; Bryan T Hennessy; Kristine Broglio; Funda Meric-Bernstam; Massimo Cristofanilli; Sharon H Giordano; Thomas A Buchholz; Aysegul Sahin; S Eva Singletary; Aman U Buzdar; Gabriel N Hortobágyi Journal: Oncologist Date: 2007-08
Authors: Judith Hurley; Philomena Doliny; Isildinha Reis; Orlando Silva; Carmen Gomez-Fernandez; Pedro Velez; Giovanni Pauletti; Jodeen E Powell; Mark D Pegram; Dennis J Slamon Journal: J Clin Oncol Date: 2006-03-20 Impact factor: 44.544
Authors: Weiqiang Chen; Steven G Allen; Weiyi Qian; Zifeng Peng; Shuo Han; Xiang Li; Yubing Sun; Chelsea Fournier; Liwei Bao; Raymond H W Lam; Sofia D Merajver; Jianping Fu Journal: Small Date: 2019-01-11 Impact factor: 13.281
Authors: María Gabriela Vallone; Virginia Mariana González; José Gabriel Casas; Margarita Larralde Journal: An Bras Dermatol Date: 2018-03 Impact factor: 1.896